ABCSG 45 Summary
A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status
| Start: | 06/2019 |
| Coordinating Investigator: | Christian Singer, Vienna |
| Sample size: | 90 (national) |
| Design: (Click to enlarge) |
 |
Share on